The Fragile Genes FHIT and WWOX Are Inactivated Coordinately in Invasive Breast Carcinoma: Correlations with Clinical Features

Cancer

Volumn 100, Issue 8, 2004, Pages 1605-1614

  Guler, Gulnur ^a,b,c   Uner, Aysegul ^a   Guler, Nilufer ^a   Han, Shuang Yin ^b,c   Iliopoulos, Dimitrios ^b,c   Hauck, Walter W ^b,c   McCue, Peter ^b,c   Huebner, Kay ^b,c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Breast carcinoma; Common fragile sites; Fhit; Wwox

Indexed keywords

ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; STEROID HORMONE;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CHROMOSOME 16Q; CHROMOSOME 3P; CHROMOSOME FRAGILE SITE; CHROMOSOME LOSS; CLINICAL FEATURE; DNA DAMAGE; FEMALE; FHIT GENE; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; WWOX GENE;

ACID ANHYDRIDE HYDROLASES; ADULT; BREAST NEOPLASMS; CARCINOMA; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 1842581808     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20137     Document Type: Article

References (38)

1. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell. 2002;111:779-789.
2. Huebner K, Croce C. FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer. 2001;1:214-221.
3. Popescu NC. Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett. 2003;192:1-17.
4. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587-597.
5. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 1999;59:3333-3339.
6. Ishii H, Dumon KR, Vecchione A, et al. Potential cancer therapy with fragile histidine triad gene. Review of preclinical studies. JAMA. 2001;286:2441-2449.
7. Dumon KR, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 2001;61:4827-4836.
8. Sevignani C, Calin GA, Cesari R, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res. 2003;63:1183-1187.
9. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998;58:5032-5037.
10. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 1997;89:857-862.
11. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 1997;89:1366-1373.
12. Zanesi N, Fidanza V, Fong LY, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci U S A. 2001;98:10250-10255.
13. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce M. FHIT loss of function in human primary beast cancer correlates with advanced stage of the disease. Cancer Res. 1999;59:3866-3869.
14. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, et al. Reduced Fhit expression in sporadic and BRCA2-1inked linked breast carcinomas. Cancer Res. 1999;59:2682-2689.
15. Gatalica Z, Lele SM, Rampy BA, Norris BA. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer. 2000;88:1378-1383.
16. Yang Q, Yoshimura G, Suzuma T, et al. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res. 2001;7:3869-3873.
17. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA. Alteration of the FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect Prep. 2001;25:292-298.
18. Ginestier C, Bardou VJ, Popovici C, et al. Loss of Fhit protein expression is a marker of adverse evolution in good prognosis localized breast cancer. Int J Cancer. 2003;107:854-862.
19. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor supressor gene region. Cancer Res. 1996;56:5605-5609.
20. Driouch K, Dorion-Bonnet F, Briffod M, Champeme MH, Longy M, Lidereau R. Loss of heterozygosity on chromosome arm 16q in breast cancer metastases. Genes Chromosomes Cancer. 1997;19:185-191.
21. Buerger H, Otterbach F, Simon R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189:521-526.
22. Roylance R, Gorman P, Hanby A, Tomlinson I. Allelic imbalance analysis of chromosome 16q shows that Grade I and Grade III invasive ductal breast cancers follow different genetic pathways. J Pathol. 2002;196:32-36.
23. Buerger H, Mommers EC, Littmann R, et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol. 2001;194:165-170.
24. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 2000;60:2140-2145.
25. Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A. 2001;98:11417-11422.
26. Mangelsdorf M, Ried K, Woollatt E, et al. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res. 2000;60:1683-1689.
27. Krummel KA, Denison SR, Calhoun E, Phillips LA, Smith DI. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer. 2002;34:154-167.
28. Chang NS, Pratt N, Heath J, et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem. 2001;276:3361-3370.
29. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001;61:8068-8073.
30. Paige AJ, Taylor KJ, Stewart A, et al. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res. 2000;60:1690-1697.
31. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene. 2002;21:1832-1840.
32. Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 2002;62:2258-2260.
33. Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res. 2003;63:878-881.
34. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual (6th edition). New York: Springer-Verlag, 2002.
35. Fleming ID, Cooper JS, Hensen DE, et al., editors. AJCC cancer staging manual (5th edition). Philadelphia: Lippincott-Raven, 1998.
36. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcomes? J Surg Res. 2003;113:109-113.
37. Turner BC, Ottey M, Zimonjic DB, et al. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res. 2002;62:4054-4060.
38. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. 2000;60:2562-2566.